December 4, 2023

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

The NRG Oncology 2024 Winter Meeting is Open for Registration!

The NRG Winter Meeting will be held in-person only at the World Center Marriott in Orlando, FL from Thursday, February 15, 2024 - Saturday, February 17, 2024 with select virtual session offerings. Please visit our meeting webpage for the agenda and more information. Register here

AMENDMENTS

GENITOURINARY

NRG-GU010: Amendment 1; version date: June 2, 2023 (posted on CTSU)

GYNECOLOGIC

NRG-GY024: Amendment 4; version date: October 19, 2023 (posted on CTSU and NRG Oncology)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANK

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BRAIN

NRG-BN011: NYU Langone will be closed on Christmas Day, Monday, December 25, 2023 and New Year’s Day, Monday, January 1, 2024. Please plan tissue shipments accordingly.

4. CANCER CONTROL & PREVENTION

NRG-CC005/FORTE: Memorandum, dated December 4, 2023, re: Amendment 5 ICF Clarifications (posted on CTSU)

NRG-CC005/FORTE: FORTE Accrual Blast – December 2023 (posted on CTSU)

NRG-CC008/SOROCk: There is 1 slot remaining for the 35- <42 age block of the BSO arm. Once this slot is filled accrual will be temporarily held to allow the 35- <42 age block of the BLS arm to enroll the same number of patients. This age blocking is specified in the protocol to ensure equal distributions of patients because this is a non-randomized study. Please see protocol Section 14.5 for a description of the age blocking. 

The BSO arm, for the 35- <42 age block, will re-open once 44 more BLS arm patients are enrolled to that cohort.

NRG-CC010: The study is now open to NRG sites in Japan and South Korea. The optional biospecimen collection does not apply to sites participating in these countries.

5. GYNECOLOGIC

GOG-0210: Reminder: Biospecimens, biomarker data, clinical data, and epidemiologic data are available for request. Please visit the NRG Oncology website for more information on this important study with the overall goal of improving the outcome and/or quality of life for patients with endometrial cancer.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

6. HEAD & NECK

NRG-HN008: Reminder: Please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important.

7. LUNG

NRG-LU007: Sites must notify the NRG Biospecimen Bank via email (nrgbb@ucsf.edu) at least 24 hours prior to shipping streck tubes. Please include the protocol number, case number and tracking number in the email. The NRGBB must coordinate with another lab to process the samples and must reserve time in advance.

8. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, NRG-CC005, and NRG/SWOG S1914. Space is limited so register now and reserve your seat. The next webinar training is scheduled for Wednesday December 13, 2023.

1. A022101/ NRG-GI009: Amended to Address Enrollment Barriers

The A022101/NRG-GI009 clinical trial, also known as the “ERASur” study, recently completed a major amendment to help combat identified barriers to patient enrollment. The ERASur trial is a pragmatic randomized phase III study of total ablative therapy for patients with limited metastatic colorectal cancer. The trial will compare the standard treatment for this patient population (systemic therapy alone) to the standard treatment with the addition of total ablative therapy to all remaining metastatic sites.

Eligibility Criteria

• Patients must have newly diagnosed metastatic disease (prior definitive therapy is okay as long as it was completed 12+ months prior to metastatic diagnosis).
• Patients must have < 4 sites of disease on baseline imaging acquired prior to any systemic therapy (no limit to # of lesions per site).
• Patients may register for the study after receiving 16 weeks of systemic therapy and up to a maximum of 26 weeks of systemic therapy.

Current Statistics

• Approved Sites = 77
• Planned Enrollment = 364
• Current Enrollment = 4

More information is available on the ClinicalTrials.gov webpage for this study.

2. New NRG Oncology Presentation Slide Templates Now Available

Please start using the 2024 NRG presentation slide template for all presentations on behalf of NRG Oncology or NRG-related work. Download the new slide template here

3. NRG Oncology Research at #SABCS23

NRG Oncology investigators will be presenting at this week’s San Antonio Breast Cancer Symposium. The primary outcomes for the NRG-NSABP B-51 study will be an oral presentation and posters for ongoing clinical trials will be featured for NRG-BR007, NRG-BR008, and NRG-BR009.

4. NCI-IOTN-SITC-AAI Free Workshop - Combining Immunotherapy with Radiotherapy: Opportunities and Challenges for Clinical Translation

NCI-IOTN-SITC-AAI will be holding a free workshop of potential significance to those with an interest in basic, pre-clinical and clinical studies of radiotherapy and immunotherapy for the treatment of cancer. The workshop will be held January 16 – 17, 2023 with in-person and virtual options. Registration deadline is January 16, 2024. Registration and more information available here.

5. NRG-CC011 Study Overview Webinar – Register Today!

NRG Oncology is hosting a webinar for a developing trial, NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial. This session will be held on December 5, 2023, 12 – 1 PM ET, and led by the study chairs, Dr. Diane Von Ah, Dr. Patricia Ganz and Dr. Brenna McDonald. This trial is designed to examine whether computerized training will improve cancer-related cognitive impairment, including the ability to concentrate, learn new things, remember, and make decisions that affect daily life in breast cancer survivors. Activation is anticipated late 2023/early 2024. 

Register in advance for this meeting

After registering, you will receive a confirmation email containing information about joining the meeting.

6. Updated Financial Conflict of Interest (FCOI) Policy for NRG Oncology

Please see the updated FCOI policy which has been posted on the Policies and Bylaws page of the NRG Oncology website.

7. NRG Oncology Biospecimen Bank - Columbus Holiday Event

The NRG Biospecimen Bank - Columbus will be closed from noon-2pm EST on Monday, December 11, 2023 for staff to attend a holiday event. If you need to contact the Biospecimen Bank during this time, please leave a message and staff will respond as soon as possible.

Phone: 614-722-2865

Email: BPCBank@nationwidechildrens.org

REMINDER: Any manuscript or abstract resulting from research done under the auspices of our NCI grant awards must be processed through the NRG Publications Office before being submitted to the journal or association. Please remember to cite any pertinent grant numbers in these publications.

Please note the following upcoming meeting and abstract submission deadline dates

UPCOMING MEETINGS

American Association for Thoracic Surgery (AATS); Apr 27-30, 2024; Toronto, ON

American Head & Neck Society (AHNS); May 15-16, 2024; Chicago, IL

American Radium Society (ARS); May 2-5, 2024; Palm Springs, CA

American Society of Breast Surgeons (ABS); Apr 10-14, 2024; Orlando, FL

American Society of Clinical Oncology (ASCO) GI; Jan 18-20, 2024; San Francisco, CA

American Society of Clinical Oncology (ASCO) GU; Jan 25-27, 2024; San Francisco, CA

American Society of Colon and Rectal Surgeons (ASCRS); Jun 1-4, 2024; Baltimore, MD

San Antonio Breast Cancer Symposium (SABCS); Dec 5-9, 2023; San Antonio, TX

Society for Clinical Trials (SCT); May 19-22, 2024; Boston, MA

Society of Gynecologic Oncology (SGO); Mar 16-18, 2024; San Diego, CA

Society of Surgical Oncology (SSO) - Advanced Cancer Therapies (ACT); Feb 16-19, 2024; San Juan, Puerto Rico

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Association for Cancer Research (AACR); Apr 5-10, 2024; San Diego, CA; LBA Jan 8, 2024, 11:59 pm ET

American College of Radiology (ACR); Apr 13-17, 2024; Washington, DC; submission deadline Dec 15, 2023

American Society of Clinical Oncology (ASCO); Chicago, IL; due to publications committee Jan 23, 2024; submission deadline Feb 6, 2024, 11:59 pm ET; LBA Mar 11, 2024, 11:59 pm ET

American Society for Radiation Oncology (ASTRO); Sep 29-Oct 2, 2024; Washington, DC; due to publications committee Feb 27, 2024; submission deadline March 12, 2024; LBA Jul 12, 2024

European Society of Gynaecological Oncology (ESGO); Mar 7-10, 2024; Barcelona, Spain; LBA Jan 15, 2024

ESMO Breast Cancer; May 15-17, 2024; Munich, Germany; due to publications committee Jan 30, 2024; submission deadline Feb 13, 2024, 21:00 CET; LBA Apr 17, 2024, 21:00 CET (placeholder required)

European Society for Radiotherapy and Oncology (ESTRO); May 3-7, 2024; Glasgow, Scotland; LBA Jan 24, 2024

Oncology Nursing Society (ONS); Apr 24-28, 2024; Washington, DC; LBA Jan 11, 2024

Society of Surgical Oncology (SSO); Mar 20-23, 2024; Atlanta, GA; LBA Dec 6, 2023, 11:59 pm ET